478 related articles for article (PubMed ID: 29593010)
41. Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences.
Valla M; Vatten LJ; Engstrøm MJ; Haugen OA; Akslen LA; Bjørngaard JH; Hagen AI; Ytterhus B; Bofin AM; Opdahl S
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1625-1634. PubMed ID: 27672056
[TBL] [Abstract][Full Text] [Related]
42. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
Johansson ALV; Trewin CB; Fredriksson I; Reinertsen KV; Russnes H; Ursin G
Breast Cancer Res; 2021 Feb; 23(1):17. PubMed ID: 33526044
[TBL] [Abstract][Full Text] [Related]
43. 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Gerstenhauer M; Brockhoff G; Ortmann O
Breast Cancer Res Treat; 2015 Oct; 153(3):647-58. PubMed ID: 26369534
[TBL] [Abstract][Full Text] [Related]
44. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
45. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
46. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
Parise CA; Caggiano V
Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
48. Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes.
Lawrenson R; Lao C; Campbell I; Harvey V; Seneviratne S; Edwards M; Elwood M; Scott N; Kidd J; Sarfati D; Kuper-Hommel M
Cancer Causes Control; 2017 Dec; 28(12):1417-1427. PubMed ID: 29027594
[TBL] [Abstract][Full Text] [Related]
49. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
50. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
51. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
Wu Q; Li J; Zhu S; Wu J; Chen C; Liu Q; Wei W; Zhang Y; Sun S
Oncotarget; 2017 Apr; 8(17):27990-27996. PubMed ID: 28427196
[TBL] [Abstract][Full Text] [Related]
52. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011).
Sineshaw HM; Gaudet M; Ward EM; Flanders WD; Desantis C; Lin CC; Jemal A
Breast Cancer Res Treat; 2014 Jun; 145(3):753-63. PubMed ID: 24794028
[TBL] [Abstract][Full Text] [Related]
53. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
54. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
Kim YJ; Kim JS; Kim IA
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
[TBL] [Abstract][Full Text] [Related]
55. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
56. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
[TBL] [Abstract][Full Text] [Related]
57. Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype.
Parise C; Caggiano V
J Breast Cancer; 2016 Jun; 19(2):112-21. PubMed ID: 27382386
[TBL] [Abstract][Full Text] [Related]
58. Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.
Plichta JK; Thomas SM; Vernon R; Fayanju OM; Rosenberger LH; Hyslop T; Hwang ES; Greenup RA
Breast Cancer Res Treat; 2020 Feb; 180(1):227-235. PubMed ID: 31980967
[TBL] [Abstract][Full Text] [Related]
59. Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes.
Fendereski A; Hajizadeh E; Haghighat S; Rasekhi A
BMC Womens Health; 2022 Jul; 22(1):268. PubMed ID: 35787692
[TBL] [Abstract][Full Text] [Related]
60. Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer.
Chen PY; Cheng SH; Hung CF; Yu BL; Chen CM
Springerplus; 2013; 2():589. PubMed ID: 25674416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
